BCL11A, a key modifier in hemoglobin disorders characterized by repressing fetal hemoglobin (HbF), is associated with the clinical severity of β-thalassemia and sickle cell disease.275 Hence, gene therapy targeting BCL11A to treat the two diseases above has been tested in trials. The gene discussed is BCL11A; the disease is sickle cell disease.